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Abstract
BACKGROUND
Art therapies are advocated by national bodies, such as the United Kingdom’s
National Institute for Health and Care Excellence, to alleviate the negative
symptoms associated with schizophrenia. The last decade has however, seen
several new larger well-controlled trials published suggesting an update is
timely.
AIM
To asses randomised controlled trials (RCT) of art therapies for reducing the
symptoms of schizophrenia – particularly negative symptoms.
METHODS
Searches of PubMed and Scopus were conducted until May 2019 for RCTs
examining the impact of art therapies on psychosis (positive, negative and total)
symptoms in people diagnosed with schizophrenia. Study quality was assessed
using the Cochrane risk of bias tool. Random effects meta-analyses were used to
derive overall effect sizes. Moderator analyses were conducted using both meta-
regression and categorical comparisons.
RESULTS
We identified 133 articles, of which 9 RCTs involving 948 participants (475
assigned to art therapies and 473 controls) met our inclusion criteria. Using
random effects models, we calculated pooled effect sizes (Hedges g) for end-of-
trial symptomatic outcomes. Effect sizes both for total symptoms [g = -0.27, 95%
confidence interval (CI) -0.60 to 0.05, k = 6] and for positive symptoms (g = -0.10,
95%CI -0.35 to 0.15, k = 6) were non-significant; however, we did find significant
reduction of negative symptoms (g = -0.42, 95%CI -0.70 to -0.14, k = 9). Meta-
regression revealed that negative symptom reduction was larger in trials with a
greater proportion of women and in trials with younger patients. Crucially, the
negative symptom reduction following art therapies was limited to lower quality
trials and did not emerge in trials that used blind assessment of outcomes.
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CONCLUSION
This review presents a comprehensive meta-analysis of art therapies in
schizophrenia in terms of both studies included and participant numbers. We
found that art therapies did not significantly reduce total or positive symptoms.
A "small" therapeutic effect was found for negative symptoms, but we show that
the effect is not present in blind trials and may be subject to publication bias.
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Core tip: This meta-analysis examines data from randomised controlled trials looking at
whether art therapies reduce the symptoms of schizophrenia-particularly negative
symptoms. Our study indicates that art therapies do not significantly reduce total
symptoms or positive symptoms. While we found a "small" therapeutic effect on
negative symptoms, the effect appears to reflect two forms of bias-first, no effect
emerges when trials use blind outcome assessment; second, the trials also point to the
possibility of publication bias.
Citation: Laws KR, Conway W. Do adjunctive art therapies reduce symptomatology in
schizophrenia? A meta-analysis. World J Psychiatr 2019; 9(8): 107-120
URL: https://www.wjgnet.com/2220-3206/full/v9/i8/107.htm
DOI: https://dx.doi.org/10.5498/wjp.v9.i8.107
INTRODUCTION
Over the past  60 years art  therapies have been promoted as a  medium in which
individuals may engage with psychotherapy in a non-judgemental, creative space and
has been applied to numerous conditions and situations. Encompassing a variety of
non-verbal,  creative interventions, arts therapies typically combine the use of art
materials and psychotherapeutic techniques with the aim of achieving psychological
change, e.g., promoting insight and general well-being. Such interventions include not
only traditional art therapy, but also dance therapy, music therapy and body-oriented
psychotherapy (a form of therapy that involves an explicit  theory of body–mind
functioning  designed  to  improve  emotional,  cognitive,  physical  and  social
integration)[1-5].
Adding adjunctive psychological interventions to pharmacotherapy has become
more common in efforts to help improve the mental state and functioning of those
living  with  schizophrenia.  While  much research  and debate  has  centred  on  the
efficacy  of  Cognitive  Behavioural  Therapy  (CBTp)  for  psychosis[6-8],  much  less
attention has been paid to the role of art therapies as an adjunctive to medication.
Art therapies may have some potential advantages over more traditional talk-based
psychological interventions for those diagnosed with schizophrenia. For example,
individuals experiencing the negative symptoms of schizophrenia (e.g., impoverished
speech) may find it difficult to verbally communicate their thoughts and emotions to a
conventional  therapist.  Art  therapies  therefore  are  unique  in  their  potential  to
circumvent this obstacle, with a nuanced relationship between the service-user, the
therapist and the artwork itself[6].
The first systematic review undertaken by the Cohrane Collaboration[9] was limited
to two small underpowered traditional art therapy trials and they concluded that
“There is no evidence to support the use of art therapy as part of policy” (p. 12). The
Cochrane review was updated two years  later[10]  although it  failed to locate  any
further studies. Later meta-analyses by the National Institute of Clinical Excellence
(NICE,  2009)[11]  refer  more broadly to  art  therapies  (including art  therapy or  art
psychotherapy, dance movement therapy, body psychotherapy, drama therapy and
music therapy) and featured 5 randomised controlled trials  (RCTs).  While NICE
reported that art therapies did not significantly reduce total symptoms [-0.49 (-0.98 to
0.01),  k  = 4] or positive symptoms [0.06 (-0.67 to 0.79),  k  = 2] at end-of-trial,  they
reported a significant benefit in reducing negative symptoms [-0.59 (-0.83 to -0.36), k =
5]. Nonetheless, the findings were somewhat limited– based on five trials involving
only 148 receiving art  therapies and 146 controls in total.  Despite this,  the NICE
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recommendation 1.4.4.3 asserts that “…clinicians should offer art therapies to all
people with schizophrenia, particularly for the alleviation of negative symptoms”. As
currently practised in the United Kingdom, arts therapies comprise: Art therapy or art
psychotherapy, dance movement therapy, body psychotherapy, drama therapy and
music therapy.
By contrast,  however,  the latest  treatment guideline published by the Scottish
Intercollegiate Guidelines network (2013)[12], came to a quite different conclusion that
“There is insufficient high-quality evidence on which to base any recommendation for
arts therapies in general” (p.  25).  In a similar vein,  and more recently,  the Royal
Australian and New Zealand College of Psychiatry[13] concluded that the evidence
from RCTs “is  inconclusive” and that  more research and assessment is  required
before art  therapy could be recommended. In the most recent systematic  review
covering studies published from 2007 onwards, Attard and Larkin (2016)[14] concluded
that while “High quality quantitative articles provided inconclusive evidence for the
effectiveness of art therapy in adults with psychosis…high-quality qualitative articles
indicated  that  therapists  and  clients  considered  art  therapy  to  be  a  beneficial,
meaningful and acceptable intervention, although this conclusion was based on a
small number of studies” (our italics).
A central suggestion for future research proposed by NICE in their 2009 CG178
guideline was that "an adequately powered RCT should be conducted to investigate
the clinical and cost-effectiveness of arts therapies as compared to an active control in
people with schizophrenia" (p. 200). Since this recommendation, the two largest-ever
clinical trials have been conducted. Both trials unequivocally reported no significant
alleviation of negative symptoms for those receiving art therapies vs their respective
control group. Crawford et al[15] note that while “many service users greatly value
using art materials and taking part in other creative activities, the widespread referral
of people with established schizophrenia to group art therapy as delivered in this
study did not lead to measurable improvements in patient outcomes or provide a cost
effective use of resources” (p. 41). Slightly more positively perhaps, Priebe et al[16]
concluded that  their  study “…does not  support  group body psychotherapy as  a
treatment for negative symptoms of schizophrenia. Reviewing the effectiveness of
different arts therapy modalities separately may be informative to determine whether
existing  guidelines  should  be  more  cautious  in  recommending  art  and  body
psychotherapy specifically, or whether this extends to arts therapies as a whole” (p.
7).
Conflicting conclusions concerning the efficacy of art therapies for individuals
diagnosed  with  schizophrenia  may  reflect  several  factors  including  that:  Meta-
analytic data are now a decade-old, the initial body of clinical research was modest
and earlier RCTs may not have been as well-controlled as more recent trials. With
several larger, appropriately powered and better-controlled trials published since the
NICE guidance in 2009,  it  seems timely to re-assess whether art  therapies aid in
alleviating the symptoms of schizophrenia, particularly negative symptoms. This
review will also conduct separate analyses assessing any impact on both positive and
total symptoms. Finally, we examine whether blinding of the outcome assessment has
a mediating effect on results (something that has not been examined in previous meta-
analyses, including NICE guidance).
MATERIALS AND METHODS
A  literature  review  was  conducted  in  accordance  with  Preferred  Reporting  for
Systematic Reviews and Meta-analysis guidelines[17] (for checklist, see appendices).
The search strategy involved identifying peer-reviewed articles published in English
since the NICE review[9] and so included the period of 2008 to May 2019 (earlier trials
were retrieved from the NICE review).
We searched the electronic databases PubMed and Scopus according to the PICO
strategy  (Patients:  Diagnosed  with  schizophrenia;  Intervention:  Arts  therapies;
Comparator:  Any control  group;  and Outcome: Symptom measures).  The search
terms  were  comparable  to  those  originally  used  by  NICE  and  included:  (1)
“schizophrenia” OR “psychosis” OR “schizo*” paired with the descriptors; (2) “art
therapy” OR “arts  psychotherapy” OR “creative arts  therapy” using all  possible
combinations.  The  comparator  was  a  control  group  of  any  description  and  the
outcome  was  negative  (positive  or  total)  symptom  measures  (see  below).  The
electronic search was supplemented by "hand-searching" of obtained article reference
lists for any trials not identified by the online searches.
Our inclusion criteria closely mirrored those used by NICE, with studies included
(Figure 1) if after the initial screening of title, abstract and keywords, they featured: (1)
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A formal diagnosis of schizophrenia, in accordance with standardised diagnostic
criteria e.g., DSM-V; (2) A randomised control trial with ≥ 10 participants per arm; (3)
A parallel control group of any type as a comparator, i.e., an active control, waitlist or
treatment as usual; (4) An intervention of art therapy, both individual or group, which
could also include variations, i.e., dance therapy, music therapy; (5) Reporting means,
standard deviation and sample size for a measure of negative symptoms; and (6) The
full-text was available in English.
Data extraction and procedure
Effect sizes were derived from the post-intervention symptom rating scores using
Hedges g (i.e., the standardized mean difference using group means divided by the
pooled standard deviation, corrected for the tendency towards overestimation in
small studies). The scales used included: the positive and negative symptom subscales
of the PANSS, the Schedule for the Assessment of Positive Symptoms, the Schedule
for the Assessment of Negative Symptoms; and the Brief Psychiatric Rating Scale. All
analyses used random effects models were conducted using Comprehensive Meta-
Analysis  (Version  2).  We  examined  studies  for  possible  follow-up  assessments
(ranging from 12 weeks to 2-years after initial post-data measurements); however, the
limited number of studies with relevant data meant that no analyses were feasible for
follow-up. If data were unavailable in a paper, authors were contacted. Effect sizes are
described using Cohen’s convention: an effect size of 0.20 was considered small, 0.50
moderate, and 0.80 large.
Heterogeneity was examined by calculating I². Following Higgins et al[18] (2011), we
interpreted I² values of 0-40% as suggesting that heterogeneity may not be important,
30%-60% representing moderate heterogeneity, 50%-90% substantial heterogeneity,
and 75%-100% as  potentially  representing considerable  heterogeneity.  Potential
publication bias was examined using Duval et al[19]’s (2000) trim and fill method.
Data pertaining to participants age (mean age range 35.4 to 41,  k  = 9),  gender
(proportion of males: 0.43 to 0.73, k = 9), duration of illness (years: 8.9 to 12.8, k = 5),
and the number of therapy sessions (8 to 72, k = 9) were also extracted, for potential
moderator analyses using meta-regression. Despite no definitive minimum number of
studies being required to complete a meta-regression, a general recommendation
proposed by Cochrane is at least 6 to 10 studies for a continuous variable[14]. On this
criterion, moderator variables which failed to meet this minimum requirement were
not selected for further analysis and as such, meta-regressions were only conducted
on gender (percentage of participants that were male) and the total number of therapy
sessions in each study; the latter of which was proposed as a topic of future research
by NICE[9].  Data relating to blinding the assessment of outcome was extracted to
examine any effects on the primary outcome variable i.e., negative symptoms.
Risk  of  bias  was  using  the  Cochrane  risk  of  bias  tool  (RoB2)[20]  covering  the
following  areas  of  potential  bias:  Sequence  generation,  allocation  concealment,
blinding of participants, blinding of outcome assessors, incomplete outcome data,
selective reporting, researcher allegiance.
RESULTS
Following our search a total of 9 articles were included for the final review[15,16,21-27]
(Table 1 and Figure 1), providing a sample of 948 participants: 475 randomly assigned
to art therapies including conventional art therapy (k = 3), music therapy (k = 3), body-
oriented psychotherapy (k = 2) and dance therapy (k = 1); and 473 were assigned to
control conditions.
Risk of bias
Risk of bias was assessed using the RoB2[16]. The RoB tool assess five areas of potential
bias in trials: (1) Bias arising from the randomisation process (randomisation and
allocation  concealment);  (2)  Bias  due  to  deviations  from intended interventions
(blinding of participants and personnel); (3) Bias due to missing data (incomplete
outcome  data);  (4)  Bias  in  measurement  of  the  outcome  (blinding  of  outcome
assessment); and (5) bias in selection of the reported result (selective reporting).
Using these criteria, 3 trials were overall at high risk of bias[17,20,23]; the remaining 6
showed "some concern" (Figure 2), largely reflecting the inability of participants to be
blind to whether they received the psychological intervention or control.
Effect sizes
The pooled effects size for the 6 studies of total symptoms was nonsignificant [g = -
0.27, 95% confidence interval (CI) -0.60 to 0.05, P  = 0.10]. These studies were also
heterogeneous (Q = 24.5, P < 0.001) with an I² value of 79.6. For forest plot see Figure 3
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Figure 1
Figure 1  PRISMA flow diagram.
(negative  sign favours  art  therapies).  The  pooled effect  size  for  the  6  studies  of
positive symptoms was non-significant (g = -0.10, 95%CI -0.34 to 0.15, P = 0.44). The
studies were again heterogeneous (Q = 11.2, P = 0.05) with an I² value of 55.4 (Figure
4). The pooled effect size was for negative symptoms in 9 trials was significant (g = -
0.42, 95%CI -0.70 to -0.14, P = 0.004). The studies were heterogeneous (Q = 31.3, P <
0.001), with an I² value of 74.4 (Figure 5).
Examination of publication bias was assessed using Duval and Tweedie’s trim and
fill[19], indicated 5 potentially missing studies–adjusting for these studies reduced the
effect size to -0.01 (95%CI -0.13 to 0.10), which became nonsignificant (Figure 6). We
also analysed possible bias using Egger’s[28] regression intercept and this confirmed
significant funnel plot asymmetry (P < 0.01; 2 tailed).
Moderator analyses
Meta-regressions were run on samples with a minimum of 6 trials[18], which included
the influence of  gender (the proportion of  male participants)  and the number of
therapy sessions. Table 2 provides a summary of the meta-regressions completed in
this review (see below).
Trials  with  a  greater  proportion  of  female  participants  and  with  younger
participants reported significantly larger effect sizes for the alleviation of negative
symptoms  (Figure  7).  The  number  of  therapy  sessions  offered  to  participants
throughout  each trial,  ranging from 8 forty-five-minute  sessions to  72  two-hour
sessions, was not a significant predictor of the effect size for negative symptoms.
Turning to categorical variables, trials with high risk of bias had significantly larger
effect sizes than those at lower risk of bias [(g = -0.82, -1.14 to -0.50, k = 3) vs (g = -0.15,
-0.37 to 0.10, k  = 6),  Q = 11.59, df  = 1, P  < 0.001].  We assessed the specific impact
blinding of outcome assessment as a categorical moderator for negative symptoms.
The pooled effect size for 6 blind studies was nonsignificant (g = -0.15, 95%CI -0.37 to
0.06, P = 0.17), whereas that in 3 non-blind studies was highly significant (g = -0.82,
95%CI -1.14 to -0.50, P < 0.001). The effect size for blind trials was significantly smaller
than that for nonblind trials (Q = 11.55, df=1, P < 0.001, Figure 8). Heterogeneity was
non-significant for both blind and nonblind trials (Q = 8.78, df = 5, P = 0.12, I2 = 43.16;
Q = 2.39 df = 2, P = 0.30, I2 = 16.26, respectively).
DISCUSSION
A key aim of the current paper was to analyse evidence from RCTs regarding the
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Table 1  Trials included in the meta-analyses
Art (n) Control (n) Blind assess Sessions Control Art therapy type
Yang et al[21], 1998 40 30 No 6 per week × 3 mo TAU Music
Röhricht et al[22], 2006 24 121 Yes 20 over 20 wk Supp couns Body-oriented psychotherapy
Ulrich et al[23], 2007 21 16 Yes Mean = 7.5 TAU Music
Richardson et al[24], 2007 43 47 No 12 TAU Art
Talwar et al[25], 2008 33 48 Yes Median = 8 TAU Music
Crawford et al[15], 2010 140 137 Yes Weekly for 12 mo Activity Group art therapy
Montag et al[26], 2014 16 19 Yes 12 over 6 wk TAU Psychodynamic art therapy
Lee et al[27], 2015 18 20 No 1 per week × 12 wk TAU Dance/movement
Priebe et al[16], 2016 140 135 Yes 20 Pilates Body psychotherapy
efficacy of art therapies to reduce the symptoms of schizophrenia, especially negative
symptoms. Like previous meta-analyses[9-11], we found no significant benefit of art
therapies  in  reducing  total  symptoms  or  positive  symptoms.  On  the  key  claim
regarding negative symptoms, we did find a significant reduction, thus replicating the
earlier finding reported by NICE[9]. Crucially, however, this interpretation must be
qualified – as any symptom reduction was subject to potential biases.
Although overall bias - as assessed by the RoB2[20] - was not high in most trials,
trials at high-risk did produce significantly larger effect sizes for negative symptoms.
An issue of central concern is that effect sizes were exaggerated considerably by non-
blind assessment of outcomes. The pooled effect size for 3 non-blind trials was more
than five-times larger than that for 6 blind trials (-0.82 vs -0.15). This accords with
observations at the level of individual RCTs, where each of the 3 non-blind trials
produced moderate-large  significant  effect  sizes,  while  5  out  of  6  blinded trials
produced nonsignificant outcomes. The failure to use blind assessment clearly inflates
the  apparent  efficacy  of  art  therapies  and crucially,  this  source  of  bias  was  not
assessed in previous meta-analyses. Such effect size inflation in unblinded trials is
well-documented in medicine[29-32],  but the impact is exacerbated in trials that use
more  subjective  measures  such  as  clinician  rating  scales  to  assess  symptomatic
outcomes[26].  The same bias has been reported in trials  of  CBT for schizophrenia,
where effect sizes are inflated between 4 and 7 times by non-blind compared to blind
outcome assessment for various symptom ratings[6]. This inflation is in the same range
as that documented here for art therapies where unblinded assessment of negative
symptoms produced an effect size more than 5 times that for blind assessment. To put
the latter into perspective, the difference between blind and nonblind effect sizes is
larger than the mean effect size reported by NICE to underpin their recommendation
of art therapies for negative symptoms.
Evidence of possible publication bias also emerged for negative symptoms from the
trim and fill analysis (and Egger’s test) - with 5 imputed missing trials reducing the
effect  size for negative symptoms effectively to zero (regardless of  blinding).  Of
course, such tests do not provide direct evidence of publication bias and are estimates
based upon various assumptions. The influence of unblinded assessment and the
evidence of publication bias both undermine findings regarding the efficacy of art
therapies to reduce negative symptoms.
One advantage of the current study is that it almost doubles the number of trials
and more than triples the number of participants that were assessed by NICE (475 art
therapies and 473 control participants vs 148 art therapies and 146 controls analysed
by NICE). In their critique of NICE guidance (CG178), Taylor et al[33] (2015, p. 358)
allude to the issue of statistical power questioning the fact that NICE “…concludes
that there is sufficient evidence only for art therapies to be offered to service users
with psychosis and schizophrenia (recommendation 9.3.8.1) based on a limited review
of six RCTs. These RCTs had small sample sizes (n = 24-90)”. The current analysis
includes  newer  larger  trials  and  in  contrast  to  previous  meta-analyses,  was
sufficiently  powered (0.8)  with  9  trials  to  detect  the  mean effect  size  (-0.42)  we
report[34]. By contrast, the NICE analysis of art therapies was severely underpowered –
having  a  mean  power  of  just  0.37  to  detect  the  overall  effect  size  for  negative
symptoms reported here.
The recent additions of the MATISSE[15] and Priebe et al[16] trials provide – to date -
the largest RCTs assessing art therapies. These two studies are the only published
trials that are sufficiently powered (at 0.83 and 0.82 respectively) to detect the modest
effect size reported in this meta-analysis; and both reported zero effect sizes - 0.03 and
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Figure 2
Figure 2  Risk of bias in each trial according to the Cochrane RoB2 tool.
0.06 respectively. Indeed, each of these two trials alone contained almost as many
participants  as  all  5  trials  combined  in  the  NICE[11]  meta-analysis  for  negative
symptoms. Crucially both trials were also pre-registered and did not deviate from
what was proposed in terms of approach, recruitment and analyses. Nonetheless,
meta-analyses are only as reliable as the individual studies that are assessed. While
the MATISSE trial is the largest assessment of art therapy and exceptionally well-
controlled,  it  is  not  without  its  critics[35,36].  Holttum  et  al[35]  raised  a  series  of
methodological and procedural issues relating to the trial, which they believe may
have influenced the null findings. For example, although actual trial drop-out was
reasonable, attendance at sessions was often quite low. On another point, Wood[36] has
argued that the MATISSE trial failed to actually test art therapy as currently practised
in the UK. The MATISSE authors have responded to many of these points[37].  The
other  large well  conducted trial  by Priebe et  al[16]  has  also received some critical
commentary. Crawford et al[38] raise important questions concerning why so many
phase III trials, especially of complex psychological interventions such as the body-
oriented psychotherapy trial  by  Priebe  et  al[16]  fail  to  build  on earlier  promising
exploratory studies. Psychological interventions are clearly complex and Crawford et
al[38] note that they “are often relational in nature and rely even more on a clinician’s
ability  to  navigate  interpersonal  relationships  and  actively  engage  people  in
treatment” – this therefore makes them less predictable than, for example, a drug trial.
While  art  therapies  may  not  lend  themselves  as  readily  to  randomised  control
designs, current treatment guideline such as those of NICE rely heavily upon RCTs as
their gold standard evidence.
A further recommendation that NICE[11] proposed for future research was to assess
the optimal number of sessions that should be offered to people with schizophrenia.
The  number  of  trial  sessions  included  in  the  current  meta-analysis  varied
considerably - the least offered was 8[25], while the most was 72[15]. Our meta-regression
analysis revealed that number of intended sessions was not a predictor of the efficacy
of art therapies on negative symptomatology.
While we found no evidence for symptom reduction, it may be that art therapies
produce other benefits or are beneficial for some individuals and not others. Maujean
et al[4] in their systematic review concluded that “It is possible that limited exposure to
art  therapy  is  insufficient  to  bring  about  change  in  such  a  significant  illness  as
schizophrenia and …may not be expected to reduce global symptoms or enhance
overall quality of life, but could be reasonably expected to improve emotional states”
(p.  42).  Related concerns have arisen regarding the "quasi-neuroleptic"  focus on
symptom reduction in art therapies as well as other psychological interventions e.g.,
CBT for psychosis[39].  Psychological  interventions in general  and art  therapies in
particular might be better placed to focus on non-symptomatic outcomes such as
reducing distress (associated with symptoms), depression or anxiety or improving
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Figure 3
Figure 3  Forest plot of the studies in the meta-analysis for total symptoms.
functioning and quality of life; and for future trials of art therapies to consider moving
away from a symptom reduction focus[8].
As already noted, art therapy is an umbrella term that encompasses a diverse range
of  approaches  (including  dance  therapy,  music  therapy  and  body-oriented
psychotherapy) and this might account for some effect size heterogeneity. While we
included the same broad forms of art therapies indicated by NICE, the number of
trials limit assessing whether any specific approach might be more successful pursued
than others. Nonetheless, Crawford et al[15]  used a more conventional art therapy,
while Preibe et al[16] used group body psychotherapy and neither found a significant
effect.
Turning  to  the  question  of  "individuality",  some  may  benefit  more  from  art
therapies than others. In this context, our moderator analyses revealed a significantly
greater negative symptom reduction in trials with more female patients and those
who are younger. The role of patient gender requires further investigation – especially
since better outcomes for women in art therapy have been reported in other patient
groups[40].  Moreover,  since art  therapists  are  also more likely to  be women -  the
American Art Therapy Association suggest a ratio of 10 to 1 female:  Male[41],  the
relationship role itself might further be examined. Turning to age, the range was
limited and any future trials might investigate whether the benefits are greater for
those who are younger and/or have a shorter duration of illness.
Certain limitations of the current meta-analysis should be considered. The number
of randomised control trials published to date is low. Although the current analysis
did have sufficient power, the small number of trials allied to missing data did mean
that  some  planned  moderator  analyses  were  not  feasible  e.g.  length  of  illness.
Similarly, it was not possible to examine any impact of art therapies at follow-up
because it was so rarely assessed.
In  summary,  the  current  meta-analysis  found  no  evidence  that  art  therapies
alleviate positive or total symptoms in schizophrenia. Like previous meta-analyses,
we  found  some  evidence  that  they  may  alleviate  the  negative  symptoms  of
schizophrenia,  but  this  finding  did  not  emerge  in  trials  using  blind  outcome
assessment  and may also  be  prone  to  publication  bias.  In  this  context,  national
guidelines,  such as that by NICE[11]  suggesting that art  therapy reduces negative
symptoms require reconsideration.
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Table 2  Meta-regressions findings for moderator variables
Moderator variable k Q-statistic
Age 9 Q = 4.66, df = 1, P = 0.02
Percentage of female participants (%) 9 Q = 5.10, df = 1, P = 0.02
Number of therapy sessions 9 Q = 0.07, df = 1, P = 0.78
Figure 4
Figure 4  Forest plot of the studies in the meta-analysis for positive symptoms.
Figure 5
Figure 5  Forest plot of the studies in the meta-analysis for negative symptoms.
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Figure 6
Figure 6  Funnell plot outlining trim and fill estimates for imputed missing trials (dark circles) for negative symptoms.
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Figure 7
Figure 7  Regression plots showing effect size for negative symptoms against proportion of female patients per trial (top) and mean age (bottom).
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Figure 8
Figure 8  Forest plot comparing blind vs non-blinded outcome assessment. B: Blind; NB: Non-blinded.
ARTICLE HIGHLIGHTS
Research background
Art therapies are advocated by national bodies, such as the United Kingdom’s National Institute
for Health and Care Excellence, particularly to alleviate the negative symptoms associated with
schizophrenia. The last meta-analysis is now a decade old and several new larger well-controlled
trials have been recently published. A meta-analytic update is timely.
Research motivation
The present  study aimed to  assess  randomised controlled trials  (RCT)  of  art  therapies  for
reducing the symptoms of schizophrenia – particularly negative symptoms.
Research objectives
A key objective is to evaluate and update evidence for future guidelines concerning treatment
suggestions.
Research methods
A search of PubMed and Scopus was conducted until May 2019 for RCTs assessing symptomatic
outcomes following art therapy. Study quality was assessed using the Cochrane risk of bias tool.
Random effects meta-analyses were conducted using Comprehensive Meta-Analysis (version 2).
Moderator analyses were conducted using both meta-regression and categorical comparisons.
Research results
We identified 133 articles,  of  which 9 RCTs involving 948 participants (475 assigned to art
therapy and 473 controls) met our inclusion criteria. Using random effects models, we calculated
pooled effect sizes (Hedges g) for end-of-trial symptomatic outcomes. Effect sizes were non-
significant for total symptoms [g = -0.27, 95% confidence interval (CI) -0.60 to 0.05, k = 6] and
positive symptoms (g  = -0.10,  95%CI -0.35 to 0.15,  k  = 6);  however,  we did find significant
negative symptom reduction (g = -0.42, 95%CI -0.70 to -0.14, k = 9). Meta-regression revealed that
negative symptom reduction was larger in trials with a greater proportion of women and in
trials with younger patients. Crucially, the negative symptom reduction following art therapies
did not, however, emerge in trials that used blind assessment of outcomes.
Research conclusions
This review presents a comprehensive meta-analysis of art therapies in schizophrenia in terms of
both studies included and participant numbers. We found that art therapies did not significantly
reduce  total  or  positive  symptoms.  A  "small"  therapeutic  effect  was  found  for  negative
symptoms, but we show that the effect  is  not present in blind trials  and may be subject  to
publication bias.  The findings have implications for  clinical  practice  and future  treatment
guidelines (e.g., National Institute of Clinical Excellence) that have previously recommended
using art therapies to alleviate negative symptoms in people with schizophrenia.
Research perspectives
The current meta-analysis suggests that RCTs of art therapies do not provide evidence of any
reduction in total, positive or indeed, negative symptoms. The latter is important as this has been
viewed as a key aspect of art therapies in schizophrenia – being recommended in influential
national guidelines such as that by National Institute of Clinical Excellence. Future trials might
investigate whether one particular form of art therapy offers more benefit than others. They
might also look at whether younger individuals and women do benefit more than men.
WJP https://www.wjgnet.com December 19, 2019 Volume 9 Issue 8
Laws KR et al. Art therapies for schizophrenia symptoms
118
REFERENCES
1 Uttley L, Stevenson M, Scope A, Rawdin A, Sutton A. The clinical and cost effectiveness of group art
therapy for people with non-psychotic mental health disorders: a systematic review and cost-effectiveness
analysis. BMC Psychiatry 2015; 15: 151 [PMID: 26149275 DOI: 10.1186/s12888-015-0528-4]
2 Röhricht F. Body oriented psychotherapy. The state of the art in empirical research and evidence-based
practice: A clinical perspective. Body Movement Dance Psychother 2009; 4: 135-156 [DOI:
10.1080/17432970902857263]
3 Regev D, Cohen-Yatziv L. Effectiveness of Art Therapy With Adult Clients in 2018-What Progress Has
Been Made? Front Psychol 2018; 9: 1531 [PMID: 30210388 DOI: 10.3389/fpsyg.2018.01531]
4 Maujean A, Pepping CA, Kendall E. A systematic review of randomized controlled studies of art therapy.
Art Ther 2014; 31: 37-44 [DOI: 10.1080/07421656.2014.873696]
5 Hogan S. The art therapy continuum: A useful tool for envisaging the diversity of practice in British art
therapy. Int J Art Ther 2019; 14: 29-37 [DOI: 10.1080/17454830903006331]
6 Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the
symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J
Psychiatry 2014; 204: 20-29 [PMID: 24385461 DOI: 10.1192/bjp.bp.112.116285]
7 Jauhar S, Laws KR, McKenna PJ. CBT for schizophrenia: a critical viewpoint. Psychol Med 2019; 49:
1233-1236 [PMID: 30757979 DOI: 10.1017/S0033291718004166]
8 Laws KR, Darlington N, Kondel TK, McKenna PJ, Jauhar S. Cognitive Behavioural Therapy for
schizophrenia - outcomes for functioning, distress and quality of life: a meta-analysis. BMC Psychol 2018;
6: 32 [PMID: 30016999 DOI: 10.1186/s40359-018-0243-2]
9 Ruddy R, Milnes D. Art therapy for schizophrenia or schizophrenia-like illnesses. Cochrane Database
Syst Rev 2003; CD003728 [PMID: 12804485 DOI: 10.1002/14651858.CD003728]
10 Ruddy R, Milnes D. Art therapy for schizophrenia or schizophrenia-like illnesses. Cochrane Database
Syst Rev 2005; CD003728 [PMID: 16235338 DOI: 10.1002/14651858.CD003728.pub2]
11 National Collaborating Centre for Mental Health. Psychosis and Schizophrenia in Adults: Treatment and
Management. NICE Clinical Guideline 178. NICE, 2014.  Available from: URL:
http://www.nice.org.uk/guidance/cg178/ evidence/cg178-psychosis-and-schizophrenia-in-adults-full-guide
line3
12 Scottish Intercollegiate Guidelines Network. Management of Schizophrenia: A National Clinical
Guideline. SIGN 131. SIGN, 2013.  Available from: URL: http://www.sign.ac.uk/ pdf/sign131.pdf
13 Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, Kulkarni J, McGorry P, Nielssen
O, Tran N. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the
management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016; 50: 410-472 [PMID:
27106681 DOI: 10.1177/0004867416641195]
14 Attard A, Larkin M. Art therapy for people with psychosis: a narrative review of the literature. Lancet
Psychiatry 2016; 3: 1067-1078 [PMID: 27528095 DOI: 10.1016/S2215-0366(16)30146-8]
15 Crawford MJ, Killaspy H, Barnes TR, Barrett B, Byford S, Clayton K, Dinsmore J, Floyd S, Hoadley A,
Johnson T, Kalaitzaki E, King M, Leurent B, Maratos A, O'Neill FA, Osborn D, Patterson S, Soteriou T,
Tyrer P, Waller D; MATISSE project team. Group art therapy as an adjunctive treatment for people with
schizophrenia: a randomised controlled trial (MATISSE). Health Technol Assess 2012; 16: iii-iiv, 1-76
[PMID: 22364962 DOI: 10.3310/hta16080]
16 Priebe S, Savill M, Wykes T, Bentall RP, Reininghaus U, Lauber C, Bremner S, Eldridge S, Röhricht F.
Effectiveness of group body psychotherapy for negative symptoms of schizophrenia: multicentre
randomised controlled trial. Br J Psychiatry 2016; 209: 54-61 [PMID: 27151073 DOI:
10.1192/bjp.bp.115.171397]
17 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097 [PMID: 19621072 DOI:
10.1371/journal.pmed.1000097]
18 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0 2014.
[updated March 2011].  Available from: http://handbook-5-1.cochrane.org/
19 Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for
publication bias in meta-analysis. Biometrics 2000; 56: 455-463 [PMID: 10877304 DOI:
10.1111/j.0006-341X.2000.00455.x]
20 Higgins J, Savovic J, Sterne JAC, Page M, Hróbjartsson A, Boutron A.   A revised tool to assess risk of
bias in randomized trials (RoB 2.0). Available from: Available from: URL:
https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool
21 Yang WY, Li Z, Weng YZ, Zhang HY, Ma B. Psychosocial rehabilitation effects of music therapy in
chronic schizophrenia. Hong Kong J Psychiatry 1998; 8: 38-40
22 Röhricht F, Priebe S. Effect of body-oriented psychological therapy on negative symptoms in
schizophrenia: a randomized controlled trial. Psychol Med 2006; 36: 669-678 [PMID: 16608559 DOI:
10.1017/S0033291706007161]
23 Ulrich G, Houtmans T, Gold C. The additional therapeutic effect of group music therapy for schizophrenic
patients: a randomized study. Acta Psychiatr Scand 2007; 116: 362-370 [PMID: 17919155 DOI:
10.1111/j.1600-0447.2007.01073.x]
24 Richardson P, Jones K, Evans C, Stevens P, Rowe A. Exploratory RCT of art therapy as an adjunctive
treatment in schizophrenia. J Mental Health 2007; 16: 483-491 [DOI: 10.1080/09638230701483111]
25 Talwar N, Crawford MJ, Maratos A, Nur U, McDermott O, Procter S. Music therapy for in-patients with
schizophrenia: exploratory randomised controlled trial. Br J Psychiatry 2006; 189: 405-409 [PMID:
17077429 DOI: 10.1192/bjp.bp.105.015073]
26 Montag C, Haase L, Seidel D, Bayerl M, Gallinat J, Herrmann U, Dannecker K. A pilot RCT of
psychodynamic group art therapy for patients in acute psychotic episodes: feasibility, impact on symptoms
and mentalising capacity. PLoS One 2014; 9: e112348 [PMID: 25393414 DOI:
10.1371/journal.pone.0112348]
27 Lee HJ, Jang SH, Lee SY, Hwang KS. Effectiveness of dance/movement therapy on affect and psychotic
symptoms in patients with schizophrenia. Arts Psychother 2015; 45: 64-68 [DOI:
10.1016/j.aip.2015.07.003]
28 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical
test. BMJ 1997; 315: 629-634 [PMID: 9310563 DOI: 10.1136/bmj.315.7109.629]
29 Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, Ravaud P, Brorson S.
WJP https://www.wjgnet.com December 19, 2019 Volume 9 Issue 8
Laws KR et al. Art therapies for schizophrenia symptoms
119
Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both
blinded and non-blinded outcome assessors. BMJ 2012; 344: e1119 [PMID: 22371859 DOI:
10.1136/bmj.e1119]
30 Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, Ravaud P, Brorson S.
Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials
with both blinded and nonblinded assessors. CMAJ 2013; 185: E201-E211 [PMID: 23359047 DOI:
10.1503/cmaj.120744]
31 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological
quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412
[PMID: 7823387 DOI: 10.1001/jama.273.5.408]
32 Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJ, Sterne JA.
Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and
outcomes: meta-epidemiological study. BMJ 2008; 336: 601-605 [PMID: 18316340 DOI:
10.1136/bmj.39465.451748.AD]
33 Taylor M, Perera U. NICE CG178 Psychosis and Schizophrenia in Adults: Treatment and Management -
an evidence-based guideline? Br J Psychiatry 2015; 206: 357-359 [PMID: 25934299 DOI:
10.1192/bjp.bp.114.155945]
34 Cuijpers P. Meta-analyses in mental health research: A practical guide. Amsterdam, the Netherlands: Pim
Cuijpers Uitgeverij; 2016;
35 Holttum S, Huet V. The MATISSE trial–a critique: does art therapy really have nothing to offer people
with a diagnosis of schizophrenia? Sage Open 2014; 4: 1-11 [DOI: 10.1177/2158244014532930]
36 Wood C. In the wake of the Matisse RCT: What about art therapy and psychosis? Int J Art Ther 2013; 18:
88-97 [DOI: 10.1080/17454832.2013.850104]
37 Patterson S, Waller D, Killaspy H, Crawford MJ. Riding the wake: detailing the art therapy delivered in
the MATISSE study. Int J Art Ther 2015; 20: 28-38 [DOI: 10.1080/17454832.2014.993666]
38 Crawford MJ, Barnicot K, Patterson S, Gold C. Negative results in phase III trials of complex
interventions: cause for concern or just good science? Br J Psychiatry 2016; 209: 6-8 [PMID: 27369475
DOI: 10.1192/bjp.bp.115.179747]
39 Birchwood M, Shiers D, Smith J. CBT for psychosis: not a 'quasi-neuroleptic'. Br J Psychiatry 2014; 204:
488-489 [PMID: 25029689 DOI: 10.1192/bjp.204.6.488a]
40 Gussak D. Comparing the effectiveness of art therapy on depression and locus of control of male and
female inmates. Arts Psychother 2009; 36: 202-207 [DOI: 10.1016/j.aip.2009.02.004]
41 Gussak D. An interactionist perspective on understanding gender identity in art therapy. Art Ther 2008;
25: 64-69 [DOI: 10.1080/07421656.2008.10129414]
WJP https://www.wjgnet.com December 19, 2019 Volume 9 Issue 8
Laws KR et al. Art therapies for schizophrenia symptoms
120
